TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM),…
Pharmaceuticals, Biotechnology and Life Sciences
Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM),…
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted…
Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated…
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical…
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023. Article 223-16…
KEY FIGURES RevenueNine months, 2023 €925.3 million Growth at constant exchange rates and scope1 +2.8% of whichcompanion animals…
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen…
These amivantamab regimens are the first to show improvement in progression-free survival compared to chemotherapy in patients with EGFR-mutated advanced…
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen…
Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411;…